Movement Alert｜Johnson & Johnson Intraday Rise 3.1% in Regular Trading, Head and Neck Cancer Trial Data Showed 77% Tumor Response Rate

Market Focus10-26 22:03

On October 26, Johnson & Johnson rose 3.1% in Regular Trading, trading at $271.8725/share, with turnover of $238 million.

The move followed new oncology trial data released late Sunday showing that the investigational Rybrevant Faspro combination delivered a 77% confirmed response rate in a phase 1b/2 study in patients with recurrent or metastatic head and neck cancer.

Recent pipeline updates add context to the move. A separate company update said its first-in-class RIPTAC molecule JNJ-6143 produced a 75% tumor response rate in advanced prostate cancer, while earlier phase 3 data showed Tremfya maintained or improved fistula remission through 48 weeks in Crohn's disease. Even so, one broker maintained a neutral stance, arguing that valuation premium could limit upside despite strong cancer data.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment